JP7406990B2 - ヒト血漿様培地 - Google Patents

ヒト血漿様培地 Download PDF

Info

Publication number
JP7406990B2
JP7406990B2 JP2019524430A JP2019524430A JP7406990B2 JP 7406990 B2 JP7406990 B2 JP 7406990B2 JP 2019524430 A JP2019524430 A JP 2019524430A JP 2019524430 A JP2019524430 A JP 2019524430A JP 7406990 B2 JP7406990 B2 JP 7406990B2
Authority
JP
Japan
Prior art keywords
culture medium
cells
concentration
assay
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501522A (ja
JP2020501522A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド エム. サバティーニ,
ジェイソン キャンター,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of JP2020501522A publication Critical patent/JP2020501522A/ja
Publication of JP2020501522A5 publication Critical patent/JP2020501522A5/ja
Application granted granted Critical
Publication of JP7406990B2 publication Critical patent/JP7406990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/32—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of substances in solution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019524430A 2016-11-11 2017-11-13 ヒト血漿様培地 Active JP7406990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421074P 2016-11-11 2016-11-11
US62/421,074 2016-11-11
PCT/US2017/061377 WO2018089928A1 (en) 2016-11-11 2017-11-13 Human plasma-like medium

Publications (3)

Publication Number Publication Date
JP2020501522A JP2020501522A (ja) 2020-01-23
JP2020501522A5 JP2020501522A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP7406990B2 true JP7406990B2 (ja) 2023-12-28

Family

ID=62110050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524430A Active JP7406990B2 (ja) 2016-11-11 2017-11-13 ヒト血漿様培地

Country Status (6)

Country Link
US (2) US11453858B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538151B1 (cg-RX-API-DMAC7.html)
JP (1) JP7406990B2 (cg-RX-API-DMAC7.html)
CN (1) CN110121359A (cg-RX-API-DMAC7.html)
CA (1) CA3043640A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018089928A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089928A1 (en) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US20220003750A1 (en) * 2018-12-01 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Functional screen for small molecule and monoclonal antibody drug sensitivity in multiple myeloma patients
WO2020264072A1 (en) * 2019-06-25 2020-12-30 Semma Therapeutics, Inc. Enhanced differentiation of beta cells
US12297451B1 (en) * 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN113005082B (zh) * 2019-12-20 2023-08-18 苏州依科赛生物科技股份有限公司 一种t细胞无血清培养基及其应用
CN111334472A (zh) * 2020-03-27 2020-06-26 郑州鲲鹏健康科技有限公司 Pbmc体外3d胶原蛋白水凝胶培养基及其制备方法
CN112029718B (zh) * 2020-09-17 2023-04-07 深圳博雅感知药业有限公司 无血清驯化培养间充质干细胞的方法和所用的培养基
CN113230391A (zh) * 2021-05-13 2021-08-10 杭州医学院 尿酸酶在制备抗肿瘤药物增敏剂中的应用
CN114317446B (zh) * 2021-12-30 2023-12-05 广州康盛生物科技股份有限公司 一种无血清培养基用添加剂及其应用
CN114457149A (zh) * 2022-01-05 2022-05-10 中南大学湘雅二医院 筛选别嘌醇耐受的基因甲基化标志物的应用及检测试剂
CN114634910B (zh) * 2022-03-09 2024-03-08 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种胃癌细胞的培养基及其培养方法
CN116515754B (zh) * 2023-03-17 2024-01-30 创芯国际生物科技(广州)有限公司 一种脂肪肉瘤类器官、培养基及培养方法
CN116751737B (zh) * 2023-08-16 2023-11-14 上海科新生物技术股份有限公司 无血清无蛋白培养基和制备方法及其应用
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them
CN118240744B (zh) * 2024-03-06 2024-11-26 上海迈邦生物科技有限公司 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法
CN118374562B (zh) * 2024-06-26 2024-09-03 山东润德生物科技有限公司 一种用于制备n-乙酰氨基葡萄糖的发酵培养基
CN119286765A (zh) * 2024-12-10 2025-01-10 山东伯桢生物科技有限公司 类器官基础培养基及维持和促进类器官生长的方法
WO2026142011A1 (ko) * 2024-12-27 2026-07-02 주식회사 스웬 생체 샘플 기반 추모 물품 제작 장치 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510851A (ja) 1997-07-23 2001-08-07 リュークスウニベルジテート トゥ ライデン Ha−1抗原
JP2008109866A (ja) 2006-10-30 2008-05-15 Jms Co Ltd 培地添加剤、この培地添加剤を含む培地、及びこの培地を用いた細胞の培養方法
JP2014504609A (ja) 2011-01-28 2014-02-24 4エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性炎症の治療のためのIL17及びIFN−γ阻害

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62278980A (ja) * 1986-05-29 1987-12-03 Morinaga & Co Ltd 細胞増殖因子
DE544887T1 (de) 1991-06-17 1994-02-03 Life Technologies Inc Technik zur konzentration von kulturmedien.
ATE205850T1 (de) * 1991-07-05 2001-10-15 Pro Neuron Inc Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
US20070004036A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
US8849577B2 (en) * 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
US20110244502A1 (en) * 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
TWI499412B (zh) 2010-06-16 2015-09-11 亞德生化公司 苯基硫乙酸酯組合物及其使用方法
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
WO2012125533A1 (en) 2011-03-14 2012-09-20 Wellstat Therapeutics Corporation 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
WO2012141571A1 (en) 2011-04-11 2012-10-18 M Abdullah Jaffar Ali Bin Protein-free culture media products
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
US9034584B2 (en) 2011-07-29 2015-05-19 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells
WO2014017643A1 (ja) 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
CN102994441A (zh) * 2012-09-19 2013-03-27 上海瀚康生物医药科技有限公司 一种细胞培养基及其制备方法和用途
NO2760138T3 (cg-RX-API-DMAC7.html) 2012-10-01 2018-08-04
US20190100725A1 (en) * 2016-03-18 2019-04-04 Institute Of Biophysics, Chinese Academy Of Sciences Cell culture medium and culture medium supplement
WO2018089928A1 (en) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510851A (ja) 1997-07-23 2001-08-07 リュークスウニベルジテート トゥ ライデン Ha−1抗原
JP2008109866A (ja) 2006-10-30 2008-05-15 Jms Co Ltd 培地添加剤、この培地添加剤を含む培地、及びこの培地を用いた細胞の培養方法
JP2014504609A (ja) 2011-01-28 2014-02-24 4エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性炎症の治療のためのIL17及びIFN−γ阻害

Also Published As

Publication number Publication date
EP3538151B1 (en) 2024-06-26
WO2018089928A1 (en) 2018-05-17
US20190352598A1 (en) 2019-11-21
US11453858B2 (en) 2022-09-27
EP3538151A4 (en) 2020-06-10
US20230051644A1 (en) 2023-02-16
CA3043640A1 (en) 2018-05-17
CN110121359A (zh) 2019-08-13
EP3538151A1 (en) 2019-09-18
JP2020501522A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
US20230051644A1 (en) Human plasma-like medium
Gorospe et al. Mitochondrial membrane potential acts as a retrograde signal to regulate cell cycle progression
AU2016243750B2 (en) Ex vivo proliferation of epithelial cells
Mao et al. The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons
Podtcheko et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
Fujimura et al. Functional characteristics of the human ortholog of riboflavin transporter 2 and riboflavin-responsive expression of its rat ortholog in the small intestine indicate its involvement in riboflavin absorption
US20110135612A1 (en) Compositions to effect neuronal growth
Valvezan et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
CA2318379A1 (en) Identification of substances that modify cellular secretory function
CN102231984A (zh) 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
JP2020501522A5 (cg-RX-API-DMAC7.html)
US11497749B2 (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
Malz et al. Nuclear accumulation of seven in absentia homologue‐2 supports motility and proliferation of liver cancer cells
Franzolin et al. The pyrimidine nucleotide carrier PNC1 and mitochondrial trafficking of thymidine phosphates in cultured human cells
JP6677648B2 (ja) 細胞の増殖及び多能性の調節
Drago et al. DHFR2 RNA directly regulates dihydrofolate reductase and its expression level impacts folate one carbon metabolism
Opladen et al. Effect of antiepileptic drugs and reactive oxygen species on folate receptor 1 (FOLR1)-dependent 5-methyltetrahydrofolate transport
Francia et al. Sumoylation and the oncogenic E17K mutation affect AKT1 subcellular distribution and impact on Nanog-binding dynamics to chromatin in embryonic stem cells
Bornkamm et al. Burkitt’s Lymphoma and Early B Cell Transformation as Paradigms of How Epstein-Barr Virus Overcomes Apoptosis and Ferroptosis
Thakur et al. Reduced SP1‐mediated transcriptional activation decreases expression of intestinal folate transporters in response to ethanol exposure
Wang et al. p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 arrest
KR102142775B1 (ko) Tnks 억제제의 연골조직 재생 용도
Bader et al. Paracetamol treatment increases telomerase activity in rat embryonic liver cells
Sun et al. Effects of cisplatin on expression of DNA ligases in MiaPaCa human pancreatic cancer cells
US20260027190A1 (en) Ovarian tumor deubiquitinase oxidation and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231218

R150 Certificate of patent or registration of utility model

Ref document number: 7406990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150